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Albertsson et alhypoxia-ischemia (HI) secondary to prenatal infection
and/or the developmental immaturity of the cerebral
vasculature at the middle to late gestational age have been
proposed to be critical in preterm brain injury.3e5 How-
ever, the speciﬁc immune cell types and associated me-
diators involved in preterm brain injury remain poorly
deﬁned.
Accumulating evidence suggests that lymphocytes,
especially T cells, play important roles in ischemic brain
injury, such as adult stroke. Most T cells are abT cells,
but there is a small population of T cells called gdT cells.
Compared with abT cells, gdT cells are the ﬁrst
T-lymphocyte subset to arise during ontogeny,6e8 and
they are the ﬁrst population of T cells to display func-
tional responsiveness. Thus, gdT cells can contribute to
immune regulation and immune responses early in life by
compensating for the relative immaturity of abT cells in
the neonatal period.9,10 gdT cells recognize qualitatively
distinct antigens compared with abT cells, and they are
not restricted to antigen processing and antigen presen-
tation on major histocompatibility complex molecules by
professional antigen-presenting cells, such as abT
cells.11e13 gdT cells can also recognize stress-induced
cell-surface markers, and gdT cells not only respond to
infection and sterile-induced inﬂammation but also sense
the lipid ligands that are often enriched on central ner-
vous system (CNS) injury.14 Indeed, gdT cells are found
in demyelinating lesions in the CNS of patients with
multiple sclerosis15 and are detected in the mouse brain
during disease onset in the mouse model of multiple
sclerosis.16 These gdT cells are characterized as the IL-
17eproducing subtype, and they further promote IL-17
production by the ensuing CD4þ abT cells to exacer-
bate the CNS pathologic features.16 gdT cells also
aggravate ischemic brain injury and stroke in adult mice
via IL-17A production and the recruitment of neutro-
phils.17,18 Importantly, gdT cells rapidly produce IL-17
in response to the activation of innate receptors and
cytokine stimulation even without triggering the T-cell
receptor (TCR).19 The cytokines IL-17A and IL-17F are
proinﬂammatory cytokines, and the CD4þ Th17-secreting
IL-17emediated inﬂammatory response appears to play
critical roles in a rodent model of inﬂammation-sensitized
perinatal brain injury.20 The IL-10 family cytokine IL-22
has also been implicated in CNS injury, such as multiple
sclerosis,21,22 and it represents an important effector
molecule of activated Th22, Th1, and Th17 cells as well
as gdT cells.
The above evidence clearly shows that the gdT-cell/IL-
17/IL-22 axis represents an important signaling pathway in
adult brain injury. However, its role in newborn brain
injury remains largely unknown. We took advantage of
both experimental preclinical models and human subjects
to investigate the potential contribution of the gdT-cell/IL-
17/IL-22 cascade to the development of preterm brain
injury.758Materials and Methods
Mouse Model of Hypoxia-Ischemia Preterm Brain Injury
All animal experiments were approved by the Gothenburg
Ethical Committee on Animal Research. TCRd chaine
targeted mutant mice (Tcrd/, B6.129P2-Tcrdtm1Mom/J ),
Rag1 knockout mice (Rag1/, B6.129S7-Rag1tm1Mom/J )
that lack mature T cells (ie, abT cells or gdT cells) and B
cells, and C57BL/6-Trdctm1Mal/J EGFP reporter mice were
purchased from Jackson Laboratories (Bar Harbor, ME),
and IL-22 knockout mice (Il22/, B6;129S5-Il22tm1.1Lex/
Mmucd ) were purchased from the Mouse Biology Program,
University of California, Davis. All mice were bred in the
animal facility at the University of Gothenburg.
At postnatal day (PND) 4 (the day of birth was deﬁned as
PND0), different genotypes (wild type, Tcrd/, and Il22/)
of mice of both sexes were subjected to HI insult to induce
preterm brain injury according to a method described
previously.23
For brain injury evaluation, wild-type, Tcrd/, and
Il22/ mice were used. There are no commercially avail-
able IL-17Fedeﬁcient mice, but intracerebroventricular
injection of antibodies is an efﬁcient way of neutralizing
cytokines after brain injury.24 For the IL-17 depletion
experiment, a total of 1 mg (in 2 mL of phosphate-buffered
saline) of antieIL-17 antibody (0.5 mg/mL in phosphate-
buffered saline, monoclonal rat IgG2A, clone 50104,
MAB421, R&D Systems, Minneapolis, MN) or 1 mg (in
2 mL) of monoclonal rat IgG2a isotype control antibody for
IL-17 (IL-17 isotypes, 0.5 mg/mL in phosphate-buffered
saline, monoclonal rat IgG2A, clone 54447, MAB006,
R&D Systems) was injected into the left lateral ventricle
immediately before HI in PND4 mice by randomization
grouping. At 24, 48, and 72 hours after HI, pups were
further intraperitoneally injected with the antieIL-17
antibody or IL-17 isotype controls (0.5 mg/mL in phosphate-
buffered saline).Fetal Sheep Model of Asphyxia-Induced Preterm Brain
Injury
These studies were approved by the Gothenburg Ethical
Committee on Animal Research. Time-mated pregnant
sheep were anesthetized, and the fetal sheep underwent
aseptic surgery at 95 days’ gestation as previously re-
ported.25 Brieﬂy, catheters were implanted into the fetal
brachial artery and vein, and a silastic umbilical cord cuff
was placed around the umbilical cord. In case of twins, only
one fetus was instrumented, and the second uncatheterized
fetus served as a control. To induce fetal asphyxia, the cord
cuff was inﬂated and the umbilical cord was transiently
occluded for 25 minutes at 99 to 100 days gestation (full
term was approximately 147 days). At postmortem, coronal
brain sections (10 mm) at the level of the lateral ventricle
were collected and stained with thionin/acid fuchsin stainingajp.amjpathol.org - The American Journal of Pathology
gd T Cells and Preterm Brain Injuryor were stained for gdT cells using the mouse anti-bovine
WC1 primary antibody (catalog number MCA838G; AbD
Serotec, Täby, Sweden) or antibodies against glial ﬁbrillary
acidic protein (mouse monoclonal IgG; catalog number
G3893; Sigma-Aldrich, Stockholm, Sweden) and Iba-1
(rabbit polyclonal IgG; catalog number 019-19741; Wako,
Stockholm, Sweden).Table 1 Primers Used for Quantitative RT-PCR
Gene Catalog number Gene Catalog number
Traf3ip2 QT00107422 Il22ra1 QT00151277
Ahr QT00174251 Il23r QT00138719Human Preterm Infant Postmortem Brain Analysis
A written informed parental consent form was obtained
according to the Declaration of Helsinki and the guidelines
of the National Health Service UK. Ethics approval was
obtained from the National Research Ethics Service, West
London, United Kingdom. Six postmortem brains of pre-
term neonates (<36 weeks’ gestational age) with and
without PVL were obtained from the Perinatal Pathology
Department, Imperial Health Care Trust, London, United
Kingdom, and used in this study. The primary cause of
death of each case was assessed by a pathologist. The details
of each case are summarized in Supplemental Table S1.
The processing of the human postmortem brains and the
immunohistochemical (IHC) staining were performed as
described previously.26,27 The primary antibodies were anti-
human TCR (catalog number 331202, clone MG1-45;
BioLegend, San Diego, CA), anti-TCRVd1 (catalog num-
ber TCR1730; Thermo Fisher Scientiﬁc, Rockford, IL), and
anti-TCRVd2 (catalog number TCR1732; Thermo Fisher
Scientiﬁc). Staining using the isotype control antibody for
TCRgd (Mouse IgG1 Isotype Control; catalog number
02-6100; Thermo Fisher Scientiﬁc) served as the negative
control, and no speciﬁc staining was identiﬁed in this
preparation. Human tonsil tissue was used as the positive
control, and strong TCRgd-positive staining was observed.
The sections were examined by bright-ﬁeld microscopy
using a light microscope (DM6000 B; Leica Microsystems
Ltd., Bucks, United Kingdom). Immunopositive cells for
TCRVd2 were counted per high-power ﬁeld at 400
magniﬁcation (0.0426 mm2). A mean of seven counts was
made per region of interest. The high-power ﬁelds were
selected on the basis of highest density of immunopositive
cells identiﬁed within each region of interest.Maf QT01063846 Irf4 QT00109984
Hcst QT00323162 Jak1 QT00158438
Tyrobp QT00129514 Gapdh QT01658692
Ifng QT00145250 Rna18s1 QT01036875
Il1b QT01048355 Runx1 QT00100380
Il1r1 QT00095256 Stat1 QT00162183
Il2rg QT00106337 Stat3 QT00148750
Il10ra QT00112742 Sox13 QT00199570
Il17a QT00103278 Map3k7 QT00150402
Il17f QT00144347 Trg QT00307692
Il17ra QT00112063 Traf6 QT00166663
Il17rc QT01076733 Tyk2 QT00114667
Il22 QT00128324
All primers were from Qiagen.IHC Staining of Mouse Brain Sections and Assessment
of Mouse Brain Damage
At 7 days after HI, the brains were dissected, parafﬁn
embedded, and cut into 10-mm coronal sections throughout
the whole brain, and staining was performed on every 50th
section. The following primary antibodies were used: mouse
antieMAP-2 (clone HM-2; Sigma-Aldrich), mouse antie
maltose-binding protein (MBP) (SMI94; Covance,
Princeton, NJ), anti-TCRgd (catalog number ab112222;
Abcam, Cambridge, England), and anti-TCRg (catalog
number sc-1778; Santa Cruz Biotechnology, Dallas, TX).The American Journal of Pathology - ajp.amjpathol.orgThe extent of white matter and gray matter injury was
analyzed by quantitative measurements of microtubule-
associated protein (MAP) 2epositive and MBP-positive
areas in both hemispheres using a widely accepted method
as previously described28,29 with Micro Image version 4.0
(Micro-Macro AB, Gothenburg, Sweden). The investigators
(A.-M.A. and X.Z.) measuring were blinded to treatment
group. The tissue loss was calculated as follows: [(contra-
lateral hemisphere  ipsilateral hemisphere)/contralateral
hemisphere  100%].
Coronal sections at the hippocampal level were used for
all other staining. Thionin/acid fuchsin staining was per-
formed as described previously.30Quantitative RT-PCR Analysis
The mRNA expression of cytokines related to the IL-17/
IL-22 pathway in the brain at different time points after HI
in PND4 wild-type, Rag1/, and Tcrd/ mice was
analyzed by quantitative RT-PCR (RT-qPCR). A brief
intracardiac perfusion was conducted before analysis of the
brain to ensure that there were no blood contaminants in the
brain. cDNA was prepared from 1 mg of RNA in a 20-mL
reaction using the QuantiTect Reverse Transcription Kit
(Qiagen, Sollentuna, Sweden). Each PCR reaction (20 mL)
contained 2 mL of cDNA diluted 10 times, 10 mL of Quanti
Fast SYBR Green PCR Master Mix (Qiagen), and 2 mL of
PCR primer (QuantiTech Primer Assay; Qiagen) and was
run on a LightCycler 480 (Roche, Bromma, Sweden).
Primers are listed in Tables 1 and 2. Melting curve analysis
was performed to ensure that only one PCR product was
obtained. For quantiﬁcation and estimation of ampliﬁcation
efﬁciency, a standard curve was generated using increasing
concentrations of cDNA. The ampliﬁed transcripts were
quantiﬁed with the relative standard curve and normalized
against the reference gene Rna18s1 or Gapdh.759
Table 2 Custom-Made Primers for Quantitative RT-PCR
Gene Forward Reverse
Trgv1 50-CACTGGTACCGGCAAAAAGC-30 50-TCCCTCCTAAGGGTCGTTGA-30
Trgv2 50-TCGGTCACCAGAGAGACAGAT-30 50-TGCCGGTACCAATGTATAGCTG-30
Trgv4 50-AGAGCAAGAGATGAGACTGCAC-30 50-GCCGGTACCAGTGTATGGTT-30
Trgv5 50-CCACTCCCGCTTGGAAATTG-30 50-GGCACAGTAGTACGTGGCTT-30
Trgv6 50-TATGAGGCAAGGACATGGCAG-30 50-AGTTCCCGTGTCCTCTTCTGT-30
Trgv7 50-AAGGCCCGGACAAGAGGTAT-30 50-GCCCAGGAGGCACAGTAGTA-30
All primers were from Qiagen.
Albertsson et alStatistical Analysis
The sample size required for detection of signiﬁcant dif-
ferences with 80% power and a signiﬁcance level at
a Z 0.05 was determined in pilot studies using wild-type
animals, and this was estimated to be a minimum of 15
animals for injury evaluation in the mouse brain. SPSS
software version 19.0 (SPSS Inc., Chicago, IL) was used for
all analyses. Comparisons between groups were performed
with the t-test, and data with unequal variance were
compared with the Mann-Whitney U test. Analysis of
variance followed by the least signiﬁcant difference post-
hoc test was used for comparison of data from more than
two groups; P < 0.05 was considered statistically
signiﬁcant.Results
gdT Cells Are Found in the Postmortem Brains of
Preterm Infants with Brain Injury
The potential presence of gdT cells in the brains of preterm
human infants with brain injury was ﬁrst examined, and
IHC staining was performed on postmortem brain sections
from preterm infants with and without PVL (Supplemental
Table S1). Vd1þ and Vd2þ gdT cells are the major sub-
sets in preterm and term newborn infants,10 and IHC
staining showed that gdT cells were detected in the border
zone of the periventricular white matter injury areas in in-
fants with PVL and that these were Vd2þ but not Vd1þ cells
(Figure 1, AeF). Such cells were either few or completely
absent in the brains of preterm infants without evidence of
brain injury (Supplemental Table S1). The mean  SEM
number of gdT cells in the PVL cases was 13.5  5.5
cells/mm2, and such cells were absent in the control cases.
The greatest number of gdT cells was found in the brain
meninges of the PVL cases, both outside and inside the
inner layer of the blood vessels (Figure 1, GeL). These
meninges had evidence of cellular proliferation and were
much thicker than the normally thin layer of the meninges
membrane (Figure 1G). The gdT cells were found to have
three distinct morphologic structures: round and large with a
rich cytosol (Figure 1, AeE), irregular and slightly elon-
gated morphologic structure (Figure 1, H and I), or round
and large with a large nucleus and less rich cytosol760(Figure 1, JeM). The observation of large numbers of gdT
cells in the postmortem brains of preterm infants with PVL
suggests a possible correlation of gdT cells with preterm
brain injury.
gdT Cells Are Detected in the Brains of Neonatal Mice
and Sheep with Preterm Brain Injury
To explore the contribution of gdT cells to perinatal brain
injury, a well-established preclinical mouse model of pre-
term brain injury was used.23 This HI brain injury model is
generated using neonatal mice at PND4 because PND2
through PND5 is a developmental age when preoligoden-
drocytes, the most vulnerable cell types to preterm brain
injury and subsequent neurodevelopmental impairments, are
abundant in the rodent CNS,31 whereas at PND7 immature
oligodendrocytes predominate in the rodent, which overlaps
with the period between 30 weeks and term birth (36 to 40
weeks) when human immature oligodendrocytes peak in
number.
The mRNA level of the Trg gene (encoding TCRg) was
increased as early as 6 hours after HI in the ipsilateral
hemisphere of the mouse brain in the wild-type mice
(Figure 2A). Moreover, analysis of the gdT-cell subtypes in
the neonatal mouse brain after HI-induced injury showed
that they were mainly Trg-V4, 5, and 7 (Figure 2, BeD), the
same subtypes as gdT cells found in the blood, spleen,
lymph node, lung, skin, and gut in mice.32 Expression of the
other mouse TCRgd subtypes Trg-V1, 2, and 6 was unde-
tectable in the newborn mouse brain.
The accumulation of gdT cells in the mouse brain was
conﬁrmed at 6 hours after HI using IHC staining. Quanti-
ﬁcation of gdT-cell numbers (Figure 2E) showed that gdT
cells were mostly found in the border zone of the injury area
in the hippocampus, meninges, ventricle area, and the
subcortical white matter (Figure 2, EeK). Interestingly, gdT
cells in the corpus callosum white matter close to the injury
area, in both the periventricular area and the meninges,
displayed an irregular and elongated morphologic structure
with process-like features (Figure 2, F, G, I, and K).
Tcrd-H2BEGFP reporter mice, in which gdT cells are
labeled with ﬂuorescent enhanced green ﬂuorescent protein
(eGFP),33 were used to corroborate the above observation of
gdT cells in HI-injured brains. Consistent with the IHC
analysis (Figure 2, EeK), eGFP-positive gdT cells wereajp.amjpathol.org - The American Journal of Pathology
Figure 1 Vd2þ gdT cells in the postmortem brains of preterm infants with brain injury. Parafﬁn-embedded cerebral hemispheres and frontal lobe sections
at the level of Ammon’s horn, including the lateral ventricle, were used for immunohistochemical (IHC) analysis. AeE and HeM: IHC staining of Vd2þ gdT cells
(arrows) in the injured brains in the periventricular white matter region adjacent to the injured area (A), the meninges tissue (BeD), and the tissue close to
the cortex (E) of postmortem neonatal cases. Insets in A and B show higher magniﬁcation of Vd2þ gdT cells. D is a higher magniﬁcation image of C. AeE are
from case 1. F: Negative control stained with an isotype control antibody against TCRgd. G: Thionin/acid fuchsin staining of the brain meninges area. HeM:
gdT-positive staining in the meninges area of the postmortem brain outside the blood vessels, in the inner side of the blood vessels in the meninges (J), and
in the cells of the blood vessel wall (KeM). I is a higher magniﬁcation image of the boxed area in H. GeL are from case 2. Arrowhead in K indicates
IHC-positive staining of Vd2 gdT cells. Scale bars: 50 mm (A, B, E, and F); 20 mm (C, I, J, L, and M); 10 mm (D); 100 mm (G, H, and K). Original magniﬁcation,
40 (A and B, insets).
gd T Cells and Preterm Brain Injurymostly found in the border zone of the injury areas in the
ipsilateral hippocampus and in the meninges of the ipsilat-
eral hemisphere of mouse brains at 6 hours after HI
(Figure 2, LeQ).The American Journal of Pathology - ajp.amjpathol.orgThe sheep model of asphyxia-induced preterm brain
injury, a well-established preclinical model for preterm
brain injury,25 was used to further conﬁrm the ﬁndings of
gdT cells in the injured brains. Similar to cats, cows, and761
Figure 2 gdT cells are found in the mouse brain after hypoxia-ischemia (HI)einduced preterm brain injury. AeD: The mRNA expression of Trg (A), Trgv4
(B), Trgv5 (C), and Trgv7 (D) in the hemisphere ipsilateral to the injury compared with the mRNA level in the normal control mice. EeQ: Presence of gdT cells in
the mouse brain after HI injury. E: gdT-cell counts from immunohistochemical staining at 6 hours after HI. F and G: Representative immunohistochemical
staining of gdT cells at 6 hours after HI in the mouse brain in the meninges of the ventral part of the retrosplenial area (F) and in the meninges of the cortical
amygdala area (G) in the ipsilateral hemisphere. HeK: gdT cells in the contralateral (H) and ipsilateral (I) periventricular area by the anterior pretectal nucleus
(APN) and lateral posterior nucleus (LPN) of the thalamus and in the contralateral (J) and ipsilateral (K) meninges by the cortical amygdala area (COA). LeQ:
In eGFP gdT-cell reporter mice, eGFPþ gdT-cells are shown in the meninges by the cortical amygdala area in the ipsilateral hemisphere at 6 hours after HI. L:
Enhanced green ﬂuorescent proteinepositive (eGFPþ) gdT cells. N: Nuclear staining with DAPI. P: Overlay of eGFPþ gdT cells and DAPI. M, O, and Q: Higher-
magniﬁcation images of L, N, and P, respectively. Data are expressed as means  SEM of the ratio of the target gene to the reference gene Rna18s1 (AeD) and
means  SEM gdT-cell counts (E). nZ 6 to 8 (AeD, HI mice); nZ 5 to 6 (AeD, controls); nZ 8 (E, HI mice). *P < 0.05, **P < 0.01, and ***P < 0.001
versus control mice (nZ 8); yP < 0.05 between the contralateral and the ipsilateral hemispheres. Scale barsZ 10 mm (F and G); 50 mm (HeL, N, and P); 20
mm (M, O, and Q).
Albertsson et alchickens, sheep have a much greater percentage of gdT
cells in the circulation compared with humans and mice,34
making them an ideal model to investigate the importance
of gdT cells in preterm brain injury. In sheep brains with
evidence of white matter lesion, gliosis, and microglia
activation after asphyxia-induced preterm brain injury762(Supplemental Figure S1, AeF), large numbers of gdT
cells were detected that were mostly distributed in the
meninges (Supplemental Figure S1G), in the inner layer of
the blood vessels in the meninges (Supplemental
Figure S1, H and J), and in the choroid plexus epithelial
layer (Supplemental Figure S1, I and K). However, fewajp.amjpathol.org - The American Journal of Pathology
gd T Cells and Preterm Brain InjurygdT cells were observed in the periventricular white matter
injured area. The morphologic structure of gdT cells in the
sheep brains differed, depending on their location. In the
blood vessels in the meninges (Supplemental Figure S1G),
gdT cells were smooth and elongated along the inner layer
of the blood vessel, whereas gdT cells in the meninges
were elongated and somewhat irregular (Supplemental
Figure S1H). In the choroid plexus epithelial layer, gdT
cells had an irregular morphologic structure, and some of
the cells also showed process-like features (Supplemental
Figure S1I). Taking all the results together, gdT cells
were substantially increased in the injured brains of
experimental preclinical models.0
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Figure 3 The activation of the IL-17/IL-22 signaling pathways in a hypoxia-is
expression proﬁle of transcription factors, receptors, signaling adaptors, and cyto
induced preterm brain injury. Data are expressed as means  SEM of the ratio of
controls; n Z 6 to 8 for HI groups. *P < 0.05, **P < 0.01, and ***P < 0.001.
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To explore the contribution of the IL-17/IL-22 signaling
pathways to perinatal brain injury, the expression of tran-
scription factors, cytokines and chemokines, and other
molecules that have been implicated in the regulation of the
IL-17/IL-22 signaling pathways was analyzed.35
Some, but not all, of the IL-17/IL-22 pathwayerelated
genes35 encoding cytokines (Il1b and Il2rg), receptors
(Il1r1, Il23r, Il17ra, Il17rc, Il22ra1, and Il10ra), signaling
adaptors (Map3k7, Tyk2, Jak1, Traf6, and Traf3ip2), and
transcription factors (Stat3, Sox13, Maf, Runx1, and Ahr)6 hours 24 hours 7 days
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chemia (HI)einduced preterm brain injury mouse model. A and B: The gene
kines for the IL-17 (A) and IL-22 (B) pathways in the mouse brain after HI-
the target gene to the reference gene Rna18s1. n Z 5 to 6 for uninjured
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Albertsson et alwere regulated at either early (6 hours) or late (24 hours or 7
days) time points after HI (Figure 3). The expression of the
cytokine-encoding genes, Il17a and Ifng, was not detected
in the mouse brain at any of the time points examined
despite the observation that both cytokine genes were highly
expressed in the spleen and thymus. The mRNA level of
Il17f was up-regulated in the injured ipsilateral brain
hemisphere at 6 hours, but not at 24 hours or 7 days, after HI0
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Figure 4 Depletion of gdT cells but not IL-17A/F or IL-22 protects the mouse
cell depletion as seen in the subcortical white matter volume by measuring the ma
area (A, C, E, and F) and in the total tissue loss using microtubule associated prote
at 7 days after HI. A: Total volume of the subcortical white matter. B: Total br
subcortical white matter area (C) and total brain tissue loss at the different brain
level 1 refers to the frontal part of the mouse brain and level 6 refers to the poster
F) and MAP-2 (G and H) staining from the WT (E and G) and Tcrd/ (F and H) mo
Il22/ mice at 7 days after HI. M and N: The Il17f and Il22 mRNA levels in WT, Tc
matched naïve control mice at postnatal day 5 (PND5) and postnatal day 8 (PND
means  SEM of the ratio of the target gene to the reference gene Gapdh (M and N
19 antieIL-17, 15 WT, and 20 Il22/ mice (IeL); nZ 7 to 10 control mice and 8
T-cell receptor.
764(Figure 3A), and the same pattern was observed for the
mRNA of the Il22 gene (Figure 3B).
Depletion of gdT Cells, but Not IL-17A/F or IL-22,
Protect Mice from Preterm Brain Injury
Finally, to understand the contribution of gdT cells to pre-
term brain injury, mice deﬁcient in mature gdT cells0.0
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brain from hypoxia-ischemia (HI)einduced preterm brain injury. AeH: gdT
ltose-binding protein (MBP) immunohistochemical (IHC)epositive staining
in (MAP)-2 IHC staining (B, D, G, and H) in Tcrd/ and wild-type (WT) mice
ain tissue loss in the WT versus Tcrd/ mouse brain. C and D: The total
levels (D). The x axis of C and B indicates the brain levels analyzed, where
ior part of the mouse brain. EeH: Representative images of the MBP (E and
use brains at 7 days after HI. IeL: Brain injury after blocking IL-17A/F or in
rd/, and Rag1/ mouse brains at 6 hours and 3 days after HI and in age-
8), respectively. Data are expressed as means  SEM (AeD, IeL) and as
). nZ 29 Tcrd/ and 29 WT mice at 7 days after HI (AeH); nZ 20 IL-17,
to 11 HI mice (M and N). *P < 0.05, **P < 0.01, and ***P < 0.001. TCR,
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gd T Cells and Preterm Brain Injurysubjected to HI-induced brain injury at PND4 were
analyzed. Compared with wild-type mice, gdT-deﬁcient
mice had signiﬁcantly reduced brain injury after HI
(Figure 4, AeH). The neuroprotective effect was found in
both white matter (decreased white matter volume in wild-
type mice compared with gdT-deﬁcient mice after HI,
P Z 0.0005) (Figure 4, A, C, E, and F) and gray matter
(reduced tissue loss in gdT-deﬁcient mice compared with
wild-type mice after HI, P Z 0.0154) (Figure 4, B, D, G,
and H), with the most noticeable difference observed in the
middle part [white matter, levels 2 (P Z 0.01), 3
(P Z 0.001), and 4 (P Z 0.001)] (Figure 4C) and frontal-
middle part of the mouse brain [gray matter, levels 1
(P Z 0.005), 2 (P Z 0.01), and 4 (P Z 0.024)]
(Figure 4D). In addition, the degree of HI-induced brain
injury in males was similar to females (data not shown),
even though sex effects on neonatal HI brain injury have
been frequently reported.36
The contribution of gdT cells to preterm brain injury
appeared to be independent of the cytokines IL-17 and
IL-22 because antibody-mediated depletion of IL-17 or gene
deﬁciency of Il22 did not confer any beneﬁcial effect in
either the white matter or gray matter of the mouse brains
subjected to HI (Figure 4, IeL). Moreover, analysis of the
mRNA levels of Il17f (Il17a was not detectable in the brain)
and Il22 in the mouse brains of wild-type, Tcrd/, and
Rag1/ mice (which are devoid of any mature T or B
lymphocytes) showed that the increase in Il17f and Il22
mRNA expression in the wild-type mouse brains compared
with the Tcrd/ and Rag1/ mice was similar (Figure 4,
M and N), indicating that neither gdT cells nor abT cells are
the major sources of IL-17F and IL-22 in the neonatal
mouse brain after HI. These ﬁndings suggest that gdT cells
are critical cellular subsets that promote preterm brain
injury, and they appear to be functionally different from
gdT cells in adults with CNS injury because they do not act
through IL-17 or IL-22 as is seen in the adult mouse brain
with ischemic injury.17Discussion
This study provides the ﬁrst evidence that gdT cells
contribute to preterm brain injury and that similar subtypes
of gdT cells (Vg4, Vg5, and Vg7) as in the mouse skin
(Vg5), intestinal mucosa (Vg7), lung mucosa (Vg4), and
blood (Vg4)32,37 are present in the neonatal mouse brain
after HI-induced injury. However, gdT cells in the neonatal
mice with brain injury functioned independently of the IL-
17/IL-22 signaling pathways, which is markedly different
from the mechanism of action of Vg4þ gdT cells in the
other barrier tissues38,39 and in adult CNS injury.17 We also
provide the ﬁrst evidence of the existence of large numbers
of gdT cells in the sheep brain in a preclinical model of
preterm brain injury and in the brain of human postmortem
preterm infants with brain injury.The American Journal of Pathology - ajp.amjpathol.orgIn the mouse and sheep brain injury models, gdT cells
were observed in multiple locations of the injured brain.
gdT cells in the injured mouse brain were enriched in the
white matter of the corpus callosum, the meninges of the
ipsilateral hemisphere, the choroid plexus in the third
ventricle, and the lateral ventricle areas around the blood
vessels (Supplemental Figure S2), whereas most gdT cells
in the sheep brain were detected in the meninges, the
choroid plexus, and the blood vessels within the meninges
but not in the injured white matter. In the human preterm
infant brain, most gdT cells were detected in the meninges.
The differential distribution pattern possibly reﬂects their
different morphologic structures and subtypes associated
with distinct functions.
Recent studies have indicated that the meninges are one
of the sites involved in the inﬂammatory response after CNS
injury. For example, meningeal inﬂammation and immune
cell inﬁltration appear to play a prominent role in the
development of cerebral cortical gray matter pathologic
features and an accelerated clinical course of multiple
sclerosis.40 Notably, recent evidence also argues that gdT
cells are a normal component of the meninges in C57bl/6
mice.41 Furthermore, the rapid increases in gdT-cell mRNA
levels and gdT-cellepositive IHC stains in the mouse brain
at 6 hours after HI suggest that gdT cells in the neonatal
mouse brain are innate subsets and perhaps some of the gdT
cells are already resident in the brain or near the brain.
However, the possibility of trafﬁcking of peripheral gdT
cells into the brain in response to injury cannot be
completely ruled out. Indeed, recent analysis of gdT cells in
preterm and term infant cord blood has shown that Vd2 gdT
cells are mostly present in preterm infants and that Vd1 gdT
cells become the major cell population in term infants.10
The discovery of the Vd2 gdT cells in the human post-
mortem brain suggests that some of the Vd2 gdT cells in the
brain might arise from the peripheral blood.
Activation of the IL-17 and IL-22 signaling pathways in
gdT cells is the major contributor of gdT-mediated patho-
logic features in the intestinal mucosa and the skin,38,39 as
well as in adult CNS injury models.17,18 The activation of
IL-17 has also been implicated in lipopolysaccharide-
sensitized perinatal brain injury using PND7 rats.20 How-
ever, the results presented here clearly show that IL-17A
was not detectable in the brain of mice at this early age
(ie, within 1 week after birth). Furthermore, although Il17f
and Il22 expression was increased at the mRNA level in the
mouse brain soon after HI, they were not produced by the
gdT cells or the CD4 cells because the levels of Il17f and
Il22 mRNA were similar in the brains of wild-type mice as
they were in the Tcrd/ and Rag1/ mice (Figure 4, M
and N). In addition, they are unlikely to contribute to
preterm brain injury under the current experimental condi-
tions because depletion of IL-17 or IL-22 did not confer any
neuroprotection in the mouse model of preterm brain injury.
Consistent with our ﬁndings (Figure 3B), the study by Yang
et al,20 which reports that IL-17 is important in765
Albertsson et allipopolysaccharide-sensitized perinatal brain injury, found
that increased IL-17 is only observed in the brain after dual
insults (lipopolysaccharide/HI) but not in the HI-alone
group.20 Therefore, any role for the IL-17/IL-22 signaling
pathways in CNS injury is likely to be context and age
dependent. Interestingly, a report from the Seventh Inter-
national gdT-Cell Conference42 showed that gdT cells are
the major source of IL-17 in the meninges in the C57Bl/6
mouse but that these cells do not produce IL-17 until 1 week
of age, at which time meningeal gdT cells differentiate into
IL-17 producers. This ﬁnding strongly supports our ﬁnding
that gdT cells exist in the brain at an early age (PND4) and
provide fast responses to injury, but unlike their counter-
parts in the peripheral organs (eg, mucosa, skin, peripheral
circulation),43,44 they do not produce IL-17 at this early age,
and the IL-17 pathway is not the major contributor to pre-
term brain injury in the mouse model used in these
experiments.
The Vg4, Vg5, and Vg7 subtypes of gdT cells are able to
produce the proinﬂammatory cytokine interferon-g19;
however, this cytokine does not appear to be important in
this circumstance because interferon-g is not detectable in
the brain of the PND4 mouse model of preterm brain
injury.23 Nevertheless, our analysis of gdT-deﬁcient mice
clearly supports the essential role of this immune subset in
mediating the HI-induced pathologic ﬁndings in the devel-
oping brain at an early age, which might cooperate with the
later-emerging abT cells to exacerbate the CNS pathologic
ﬁndings and induce consequent behavior alterations, as
reported for other gdT-cell subsets implicated in autoim-
munity.16 This view warrants further investigation of the
molecular mechanisms underlying gdT-mediated CNS
pathologic ﬁndings.
Our ﬁndings have a bearing on efforts to seek targets for
therapeutic interventions of preterm brain injury. Targeting
gdT cells has shown promising results in the immuno-
therapy of other inﬂammatory diseases and cancer, and our
observations of a role for gdT cells in promoting preterm
brain injury provide new insights into the pathogenesis of
preterm brain injury and its associated sequelae, such as
cerebral palsy, and suggest new therapeutic avenues to
ameliorate these neurologic disorders in childhood. Most
importantly, the ﬁndings shed light on the fundamentally
different pathogenesis of brain injury in preterm infants
compared with that in term infants and adults, which has
important implications for the choice of therapeutic targets
to ameliorate the neurologic disabilities in this vulnerable
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